Urology

Biography

Biography: Chetan Mehndiratta

Abstract

Introduction: Benign prostate hyperplasia can occur up to about 50% of men by age 50 with an increase in incidence with age. The International Prostate Symptom Score (IPSS) questionnaire can help in the diagnosis and determine patient outcome. The addition of dutasteride, a 5-alpha-reductase inhibitor to silodosin can be beneficial in cases of benign prostate hyperplasia with an enlarged prostate especially in patients with co-morbid conditions like hypertension, obesity and dyslipidemia. Objective: This study has evaluated the effectiveness and safety of combination treatment of silodosin and dutasteride in Indian patients with mild to severe benign prostatic hyperplasia symptoms.
Methods: The study was a non-interventional observational study, conducted in 1695 Indian male patients with benign prostatic symptoms between 45-75 years of age. All the patients received a combination of silodosin and dutasteride for benign prostatic hyperplasia with enlarged prostate. The study results were the treating physician’s observations based on which descriptive analysis was carried out.
Results: Around 71% of the patients in this study were of more than 55 years of age.